Expertise in
10
conditions

Dr. Yuhchyau I. Chen

Radiation Oncology
University Of Rochester
601 Elmwood Ave, 
Rochester, NY 
Offers Telehealth
Expertise in
10
conditions
University Of Rochester
601 Elmwood Ave, 
Rochester, NY 

Overview

Yuhchyau Chen is a Radiation Oncologist practicing medicine in Rochester, New York.

Dr. Chen is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Lung Carcinoma, ALK-Positive Non-Small Cell Lung Cancer, and Prostatectomy.

She is actively involved in clinical research, co-authoring 102 peer reviewed articles and participating in 45 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in NY

Hospital Affiliations

Nicholas H Noyes Memorial Hospital
Strong Memorial Hospital
Highland Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

University of Rochester
601 Elmwood Ave, Rochester, NY 14642

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

45 Clinical Trials

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Enrollment Status: Suspended
Publish Date: September 04, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: August 27, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

102 Total Publications

LncDNAH5 Regulates Radiotherapy-Induced Toxicity via MDM2-Mediated Degradation of TP53BP1.
LncDNAH5 Regulates Radiotherapy-Induced Toxicity via MDM2-Mediated Degradation of TP53BP1.
Journal: International journal of radiation oncology, biology, physics
Published: February 20, 2026
Similar Doctors
Expertise in
16
conditions
Dr. Deepinder P. Singh
Radiation Oncology
Expertise in
16
conditions
Dr. Deepinder P. Singh
Radiation Oncology
Referral may be required

University Of Rochester

601 Elmwood Ave, 
Rochester, NY 
 (0.1 miles away)
585-275-5623
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Deepinder Singh is a Radiation Oncologist practicing medicine in Rochester, New York. He has been practicing medicine for over 44 years. Dr. Singh is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC).

Expertise in
30
conditions
Dr. Michael T. Milano
Radiation Oncology
Expertise in
30
conditions
Dr. Michael T. Milano
Radiation Oncology
Referral may be required

University Of Rochester

601 Elmwood Ave, 
Rochester, NY 
 (0.1 miles away)
585-273-4096
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Milano is a Radiation Oncologist practicing medicine in Rochester, New York. Dr. Milano is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Metastatic Brain Tumor, Acoustic Neuroma, and Orchiectomy.

Expertise in
13
conditions
Dr. Haoming Qiu
Radiation Oncology
Expertise in
13
conditions
Dr. Haoming Qiu
Radiation Oncology
Referral may be required

University Of Rochester

601 Elmwood Ave, 
Rochester, NY 
 (0.1 miles away)
585-275-2171
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Haoming Qiu is a Radiation Oncologist practicing medicine in Rochester, New York. Dr. Qiu is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Lung Cancer, and Squamous Cell Lung Carcinoma.

Frequently Asked Questions about Dr. Yuhchyau I. Chen

How do I make an appointment with Dr. Yuhchyau I. Chen?

You can book an appointment with Dr. Yuhchyau I. Chen by calling their office at 585-275-2171. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Yuhchyau I. Chen a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Yuhchyau I. Chen is classified as an Distinguished expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Yuhchyau I. Chen specialize in?

While Dr. Yuhchyau I. Chen is a Radiation Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Yuhchyau I. Chen participate in research or clinical trials?

Yes. Dr. Yuhchyau I. Chen has published 102 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Yuhchyau I. Chen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Yuhchyau I. Chen accept my insurance?

Dr. Yuhchyau I. Chen accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 585-275-2171 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chen's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile